Evidence map›Paper›PMID 36747647›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Fentanyl, Heroin, and Methamphetamine-Based Counterfeit Pills Sold at Tourist-Oriented Pharmacies in Mexico: An Ethnographic and Drug Checking Study.

Joseph Friedman, Morgan Godvin, Caitlin Molina, Ruby Romero, Annick Borquez, Tucker Avra, David Goodman-Meza, Steffanie Strathdee, Philippe Bourgois, Chelsea L Shover

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Joseph FriedmanCenter for Social Medicine and Humanities, University of California, Los Angeles.
Morgan GodvinThe Action Lab, Center for Health Policy and Law, Northeastern University.
Caitlin MolinaDivision of General Internal Medicine and Health Services Research, University of California, Los Angeles.
Ruby RomeroDivision of General Internal Medicine and Health Services Research, University of California, Los Angeles.
Annick BorquezDivision of Infectious Diseases and Global Public Health. Department of Medicine, University of California, San Diego.
Tucker AvraDavid Geffen School of Medicine, University of California, Los Angeles.
David Goodman-MezaDivision of Infectious Diseases, University of California, Los Angeles.
Steffanie StrathdeeDivision of Infectious Diseases and Global Public Health. Department of Medicine, University of California, San Diego.
Philippe BourgoisCenter for Social Medicine and Humanities, University of California, Los Angeles.
Chelsea L ShoverDivision of General Internal Medicine and Health Services Research, University of California, Los Angeles.
University of California, Los Angeles · USUniversity of California San Diego · USNortheastern University · US

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
UCLA-CDU CFARP30AI152501 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Warren Scott Comulada, LaShonda Spencer · 2022 to 2026
$15.6M
Real-time prediction of emerging drug use epidemics in the United StatesDP2DA049295 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BORQUEZ, ANNICK · 2019 to 2019
$2.4M
Using data science to measure the impact of opioid agonist therapy in patients admitted with Staphylococcus aureus bloodstream infectionsK08DA048163 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GOODMAN, DAVID · 2019 to 2023
$1.0M
Adoption and scale-up of long-acting medications for opioid use disorder by U.S. clinicians.K01DA050771 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOVER, CHELSEA LEIGH · 2021 to 2025
$893k
NIAID NIH HHS P30 AI152501NIDA NIH HHS DP2 DA049295NIDA NIH HHS K01 DA050771NIDA NIH HHS K08 DA048163NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

Background: Fentanyl- and methamphetamine-based counterfeit prescription drugs have driven escalating overdose death rates in the US, however their presence in Mexico has not been assessed. Our ethnographic team has conducted longitudinal research focused on illicit drug markets in Northern Mexico since 2018. In 2021-2022, study participants described the arrival of new, unusually potent tablets sold as ostensibly controlled substances, without a prescription, directly from pharmacies that cater to US tourists. Aims: To characterize the availability of counterfeit and authentic controlled substances at pharmacies in Northern Mexico available to English-speaking tourists without a prescription. Methods: We employed an iterative, exploratory, mixed methods design. Longitudinal ethnographic data was used to characterize tourist-oriented micro-neighborhoods and guide the selection of n=40 pharmacies in n=4 cities in Northern Mexico. In each pharmacy, samples of "oxycodone", "Xanax", and "Adderall" were sought as single pills, during English-language encounters, after which detailed ethnographic accounts were recorded. We employed immunoassay-based testing strips to check each pill for the presence of fentanyls, benzodiazepines, amphetamines, and methamphetamines. We used Fourier-Transform Infrared Spectroscopy to further characterize drug contents. Results: Of n=40 pharmacies, one or more of the requested controlled substance could be obtained with no prescription (as single pills or in bottles) at 28 (70.0%) and as single pills at 19 (47.5%). Counterfeit pills were obtained at 11 pharmacies (27.5%). Of n=45 samples sold as one-off controlled substances, 18 were counterfeit. 7 of 11 (63.6%) samples sold as "Adderall" contained methamphetamine, 8 of 27 (29.6%) samples sold as "Oxycodone" contained fentanyl, and 3 "Oxycodone" samples contained heroin. Pharmacies providing counterfeit drugs were uniformly located in tourist-serving micro-neighborhoods, and generally featured English-language advertisements for erectile dysfunction medications and "painkillers". Pharmacy employees occasionally expressed concern about overdose risk and provided harm reduction guidance. Discussion: The availability of fentanyl-, heroin-, and methamphetamine-based counterfeit medications in tourist-oriented independent pharmacies in Northern Mexico represents a public health risk, and occurs in the context of 1) the normalization of medical tourism as a response to rising unaffordability of healthcare in the US, 2) plummeting rates of opioid prescription in the US, affecting both chronic pain patients and the availability of legitimate pharmaceuticals on the unregulated market, 3) the rise of fentanyl-based counterfeit opioids as a key driver of the fourth, and deadliest-to-date, wave of the opioid crisis. It was not possible to distinguish counterfeit medications based on appearance of pills or geography of pharmacies, because identically-appearing authentic and counterfeit versions were often sold in close geographic proximity. Nevertheless, drug consumers may be more trusting of controlled substances purchased directly from pharmacies. Due to Mexico's limited opioid overdose surveillance infrastructure, the current death rate from these substances remains unknown.

Identifiers

PMID36747647
PMCPMC9901047
OpenAlexW4318395086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.